HY-0102

· Shanghai YingLi Pharmaceutical Co. Ltd.

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for HY-0102, covering 2024-06-13 to 2024-10-29. Get the full timeline:

Most recent: Clinical Trial Update: YL-13027 and/or HY-0102 Combined With AG Regimen Chemotherapy for Metastatic Pancreatic Cancer [Phase 1, Phase 2]